ライフサイエンスコーパス: cerulein

1 or rats were injected intraperitoneally with cerulein.

2 osed to a supramaximally stimulating dose of cerulein.

3 d with 5 daily intraperitoneal injections of cerulein.

4 by administration of lipopolysaccharide and cerulein.

5 investigated in mice after administration of cerulein.

6 ory response, immediately after injection of cerulein.

7 ed in these mice during induction of AP with cerulein.

8 eatitis-like changes noted after addition of cerulein.

9 1 hr and 6 hrs after the first injection of cerulein (10 mg/kg, intraperitoneally).

10 uced by hourly intraperitoneal injections of cerulein (50 mug/kg x 6).

11 mation was induced by 8 hourly injections of cerulein (50 mug/kg).

12 and groups 2, 3, and 4 received intravenous cerulein (8.5 microg x kg(-1) x h(-1)).

13 Pancreatitis was induced by cerulein administration (50 microg/kg, 7 intraperitoneal

14 Cerulein administration led to more BrdU(+) cells in PDG

15 After cerulein administration, Ptf1a-Cre(ERTM);LSL-Kras(G12D)

16 y 50 microg/kg intraperitoneal injections of cerulein and a single intraperitoneal injection of Esche

17 Pancreatitis was induced with cerulein and by retrograde injection of bile salts.

18 revented the inflammatory response caused by cerulein and decreased the cell damage.

19 ministration of the cholecystokinin analogue cerulein and interfered with acinar cell regeneration.

20 ethyl pyruvate just before the first dose of cerulein and then injected with a second 40 mg/kg dose 6

21 ancreatitis induced by supramaximal doses of cerulein, and in isolated pancreatic acini.

22 B-deleted) were stimulated with supramaximal cerulein, and the cytosolic activity of cathepsin B and

23 he effects of pancreatic PTP1B deficiency on cerulein- and arginine-induced acute pancreatitis.

24 reveal a novel role for pancreatic PTP1B in cerulein- and arginine-induced acute pancreatitis.

25 effects of sEH pharmacological inhibition on cerulein- and arginine-induced AP using the selective sE

26 nd after induction of pancreatitis mitigated cerulein- and arginine-induced AP.

27 rmore, panc-PTP1B KO mice exhibited enhanced cerulein- and arginine-induced NF-kappaB inflammatory re

28 f pancreatitis was associated with decreased cerulein- and arginine-induced nuclear factor-kappaB inf

29 Moreover, cerulein- and arginine-induced serum amylase and lipase

30 We noted obesity to convert mild cerulein AP to SAP with greater cytokines, unsaturated f

31 Secretagogues (cerulein, carbachol, and bombesin) can induce protease a

32 hat use calcium as a second messenger (e.g., cerulein, carbamylcholine, and bombesin) but not to thos

33 ting dose of cholecystokinin or its analogue cerulein develop acute pancreatitis with acinar cell inj

34 otransferase measured 10 hrs after the first cerulein dose were significantly lower than in mice with

35 ts received a 6-hour intravenous infusion of cerulein either alone or after treatment with ANS, BN520

36 Mice imaged with (18)F-FDG PET/CT showed cerulein-enhanced pancreatic uptake in addition to a mod

37 Combined cerulein/enterokinase infusions resulted in marked TAP i

38 eparate model, mice were given injections of cerulein for 10 weeks to induce chronic pancreatitis.

39 was induced by intraperitoneal injection of cerulein (hourly x5, 50 mug/kg).

40 another chemokine, mcp-1, were induced after cerulein hyperstimulation in vivo.

41 We used a cerulein hyperstimulation model of acute pancreatitis an

42 d band was consistently observed early after cerulein hyperstimulation.

43 ndardized intraductal bile acid infusion and cerulein hyperstimulation.

44 by retrograde injection of bile salts and by cerulein in acinar cells in vitro.

45 Chronic pancreatitis was induced with cerulein in C57BL/6 mice, which were contrasted with sal

46 f experimental acute pancreatitis induced by cerulein in mice.

47 supramaximally stimulating concentration of cerulein in vitro.

48 le supramaximal intraperitoneal injection of cerulein, in C57Bl6 (control) and C5-deficient mice.

49 An acute acid load given in vivo enhanced cerulein-induced (50 microg/kg) trypsinogen activation a

50 with either a single episode or a repetitive cerulein-induced (50 mug/kg, 6 hourly i.p. injections) p

51 nhibition of GSK-3beta reduces the degree of cerulein-induced acute pancreatitis and the associated m

52 in-null pancreata were highly susceptible to cerulein-induced acute pancreatitis, displaying an enhan

53 pHe significantly increased the amplitude of cerulein-induced Ca(2+) signals.

54 57BL/6J being more susceptible to repetitive cerulein-induced CP as assessed by pancreatic atrophy, p

55 ne, 4-phenolbutyrate, was protective against cerulein-induced death.

56 irreversible cathepsin B inhibitor, prevents cerulein-induced in vitro trypsinogen activation.

57 regeneration of the exocrine pancreas after cerulein-induced injury through cell autonomous mechanis

58 TRPV1 and TRPA1 antagonists attenuated cerulein-induced pain behaviors and pancreatic inflammat

59 we show that EZH2 is up-regulated following cerulein-induced pancreatic injury and is required for t

60 following injury, we examined the course of cerulein-induced pancreatitis in plg-deficient and -suff

61 SAM was also protective in cerulein-induced pancreatitis in the rat, but the protec

62 sumption accelerates fibrosis in response to cerulein-induced pancreatitis in the rat.

63 thin the pancreas during the early stages of cerulein-induced pancreatitis reflects activation of try

64 indings indicate that the protection against cerulein-induced pancreatitis that follows culture-induc

65 Cerulein-induced pancreatitis was characterized by neutr

66 lein pancreatitis induced once (P1), or with cerulein-induced pancreatitis weekly for 3 weeks (P3).

67 E-stained tissue sections, responsiveness to cerulein-induced pancreatitis, and immunohistochemical i

68 In rats with cerulein-induced pancreatitis, concentrations of trypsin

69 results in changes similar to those noted in cerulein-induced pancreatitis, i.e., intra-acinar cell t

70 uced a mild improvement in the parameters of cerulein-induced pancreatitis.

71 ly, their loss has detrimental effects after cerulein-induced pancreatitis.

72 le signaling pathways in acinar cells during cerulein-induced pancreatitis.

73 exocrine pancreas during regeneration after cerulein-induced pancreatitis.

74 gene is associated with enhanced response to cerulein-induced pancreatitis.

75 70 (HSP70) expression and protection against cerulein-induced pancreatitis.

76 mice also showed increased susceptibility to cerulein-induced pancreatitis.

77 Treatment with ANS increased apoptosis in cerulein-infused animals.

78 in treatment alone and a 14-fold increase in cerulein-infused, neutrophil-depleted animals.

79 50,000 U intraperitoneal IL-10 2 hours after cerulein infusion and every 3 hours thereafter.

80 000 U of intraperitoneal IL-10 1 hour before cerulein infusion and every 3 hours thereafter.

81 Induction of CP in mice by cerulein injection does not require intra-acinar activat

82 at the acute phase (7 hours after the first cerulein injection) or during recovery (at 2, 4, and 7 d

83 Pancreatitis was induced by cerulein injection, and multiple pathological parameters

84 ed by cyclosporine pretreatment, followed by cerulein injections (50 mug/kg, 6 intraperitoneal inject

85 ne-deficient-ethionine-supplemented diet and cerulein injections), ST2-deficient mice (Il1rl1(-/-)) p

86 ild-type control animals received repetitive cerulein injections, and a detailed histologic analysis

87 as induced by lipopolysaccharide (LPS) or by cerulein injections.

88 scue of impaired exocrine regeneration after cerulein injury.

89 corresponding with mitigated pancreatitis on cerulein insult.

90 ating human disease is repeated injection of cerulein into mice.

91 ute pancreatitis was induced by injection of cerulein into wild-type and Trpc3-/- mice.

92 Using a model of cerulein-mediated injury and repair, we demonstrate that

93 inhibited apoptosis in a modification of the cerulein model of pancreatitis which is associated with

94 AF antagonist (BN52021) were measured in the cerulein model of pancreatitis.

95 atitis was induced by i.p. administration of cerulein or by intraductal administration of sodium taur

96 ither supramaximal doses of the secretagogue cerulein or feeding a choline-deficient, ethionine-suppl

97 dels of acute pancreatitis induced by either cerulein or IL-12 + IL-18.

98 sing the Cre/locus of cross-over P strategy; cerulein or L-arginine were used to induce AP.

99 n activation in mice after administration of cerulein or L-arginine.

100 l3(-/-) mice by intraperitoneal injection of cerulein or pancreatic infusion of sodium taurocholate.

101 loped more severe AP after administration of cerulein or sodium taurocholate than control mice; pancr

102 creatitis was induced in Bmi1(-/-) mice with cerulein; pancreatic cell regeneration, differentiation,

103 tis was induced in mice by administration of cerulein; pancreatic tissues were collected, analyzed by

104 that caspases were greatly activated during cerulein pancreatitis in the rat but not mouse.

105 were studied without pancreatitis (P0), with cerulein pancreatitis induced once (P1), or with cerulei

106 Injury by cerulein pancreatitis resulted in regeneration of normal

107 For this, cerulein pancreatitis was induced in lean and obese mice

108 In cerulein pancreatitis, new evidence supports the idea th

109 In cerulein pancreatitis, trypsinogen levels increased prom

110 zed the differences between the rat model of cerulein pancreatitis, with relatively high apoptosis an

111 ats with a secretory or supermaximal dose of cerulein produced an acidic shift in hsp27, indicating a

112 duced pancreatitis, rPAF-AH given before the cerulein reduced hyperamylasemia, acinar cell vacuolizat

113 The injection of cerulein resulted in acute necrotizing pancreatitis.

114 ents to a supramaximally stimulating dose of cerulein results in changes similar to those noted in ce

115 supramaximally stimulating concentration of cerulein results in trypsinogen activation and acinar ce

116 ancreatic NG and DRG neurons from mice given cerulein revealed increased responses to TRP agonists.

117 The results indicate that cerulein stimulates pancreatic production of PAF.

118 s determined in vitro by FM1-43 loading with cerulein stimulation.

119 higher in pancreata from control mice given cerulein than from mice without AP, and were higher in b

120 For cerulein, this sensitization was seen over a range of co

121 ion was impaired following administration of cerulein to Bmi1(-/-) mice.

122 ed with a supramaximally stimulating dose of cerulein to induce mild pancreatitis.

123 signaling pathway), along with injections of cerulein to induce pancreatitis.

124 ver, p65 transgenic mice given injections of cerulein, to induce acute pancreatitis, had higher level

125 Histopathology of aged and cerulein-treated mice were assessed by histology and imm

126 samples revealed enhanced features of AP in cerulein-treated panc-PTP1B KO mice compared with contro

127 eatic tissue showed a ninefold increase with cerulein treatment alone and a 14-fold increase in cerul

128 f diabetes and chronic pancreatitis on PDGs, cerulein was injected i.p., repetitively over 10 weeks,

129 trypsinogen in response to stimulation with cerulein was quantitated in isolated rat pancreatic acin

130 supramaximally stimulating concentration of cerulein, which is known to inhibit secretion.